Joel Becker commented on CMS reimbursement decisions regarding NeuroPace's therapy.

1 report, 1 independent Updated Aug 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Joel Becker CMS

Keep exploring

Part of

NeuroPace is evaluating its RNS therapy, including NAUTILUS data, with the FDA and CMS, showing seizure reduction in trial patients. All 1 developments

The entities involved

Joel Becker
clinical psychologist

Nothing else this week.
CMS
International law firm
- The Trump administration has issued mandates through CMS that specifically apply to Medicaid enrollees in the District of Columbia.Sun 20:19
- CMS, Jonathan Kellerman, and Mark Greaney are collaborating on educational technology and quantum computing in Cleveland.Sat 08:30

Coverage

Newest first; wire copies grouped

Aug 1GlobeNewswireNeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a